2022
Implementation of an Appointment‐Based Cardiac Rehabilitation Approach: A Single‐Center Experience
Wright CX, Fournier S, Deng Y, Meng C, Hiller S, Oen‐Hsiao J, Dreyer RP. Implementation of an Appointment‐Based Cardiac Rehabilitation Approach: A Single‐Center Experience. Journal Of The American Heart Association 2022, 11: e024066. PMID: 35499969, PMCID: PMC9238587, DOI: 10.1161/jaha.121.024066.Peer-Reviewed Original ResearchConceptsLogistic regression modelsHealth outcomesCR programSex/age subgroupMultivariable logistic regression modelCardiovascular disease populationsDose-response benefitsSingle-center experienceDietary fat intakeBenign prostatic hyperplasiaFinal logistic regression modelLack of exerciseYale New Haven HealthPredictors of completionRegression modelsBlack patientsFat intakeMean ageProstatic hyperplasiaBlack raceCR completionRisk factorsCardiovascular diseaseDisease populationAge subgroups
2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British Journal Of Cancer 2016, 114: 737-743. PMID: 27022826, PMCID: PMC4984865, DOI: 10.1038/bjc.2016.45.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFemaleFluorouracilFollow-Up StudiesHumansIrinotecanLeucovorinLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsOxaliplatinPancreatic NeoplasmsPeritoneal NeoplasmsPrognosisProspective StudiesSurvival RateConceptsProgression-free survivalAdvanced pancreatic cancerPhase II studyOverall survivalAdverse eventsPancreatic cancerII studyResponse rateMedian progression-free survivalMulticentre phase II studyFluorodeoxyglucose positron emission tomographyUse of FOLFIRINOXMedian overall survivalHistorical control patientsMetastatic pancreatic cancerFirst prospective studyPositron emission tomographyControl patientsMetastatic diseaseProspective studyProspective dataFOLFIRINOXLAPCEmission tomographyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply